# Endocannabinoid System & GLP-1 Receptor Mental Health Research > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-receptor-agonists-mental-health-research/ > **Published:** 2026-04-18T12:15:58-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:55:51-04:00 > **Clinical Summary:** Explore GLP-1 receptor agonists mental health research revealing potential impacts on schizophrenia and other mental illnesses through genetic analysis. --- #### Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied for their potential causal effects on ten common mental health conditions using genetic analysis methods that reduce confounding. This type of study design helps establish whether the drug class itself may influence mental illness risk, rather than simply reflecting associations seen in observational data. Clinicians and patients should follow this emerging research area closely, as findings could have meaningful implications for how these widely prescribed medications are selected and monitored in people with co-occurring mental health conditions. ### #29 Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. **Citation:** Xiang Longgang et al. *Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.* International journal of molecular sciences. 2025. PMID: 40141382. **Study type:** Journal Article, Meta-Analysis  |  **Topic area:** Autism  |  **CED Score:** 10 Design: 6 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Abstract:** Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, post-traumatic stress disorder, schizophrenia, [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), and alcohol use disorder. We selected GLP1RA as the exposure and conducted a Mendelian randomization (MR) analysis. The cis-eQTLs of the drug target gene GLP1R, provided by eQTLGen, were used to simulate the pharmacological effects of GLP1RA. Type 2 diabetes and BMI were included as positive controls. Using data from both the Psychiatric Genomic Consortium and FinnGen, we conducted separate MR analyses for the same disease across these two independent databases. Meta-analysis was used to pool the results. We found genetic evidence suggesting a causal relationship between GLP1RA and a reduced risk of schizophrenia [OR (95% CI) = 0.84 (0.71-0.98), I2 = 0.0%, common effects model]. Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI. However, the findings of this study provide insufficient evidence to support a causal relationship between GLP1RA and other mental illnesses. Sensitivity analyses did not reveal any potential bias due to horizontal pleiotropy or heterogeneity in the above results (p > 0.05). This study suggests that genetically proxied activation of glucagon-like peptide-1 receptor is associated with a lower risk of schizophrenia. GLP1R is implicated in schizophrenia pathogenesis, and its agonists may exert potential benefits through [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/). Our study provides useful information for understanding the neuropsychiat  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40141382/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942543/)[DOI ↗](https://doi.org/10.3390/ijms26062741) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System & GLP-1 Receptor Mental Health Evidence](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) Detailed evidence on the relationship between the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), GLP-1 receptors, and mental health outcomes. [Read More](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) [Endocannabinoid System & GLP-1 Receptors: Clinical Evidence](https://cedclinic.com/glucagon-like-peptide-1-receptor-agonists-mental-health-evidence/) Clinical studies exploring GLP-1 receptor agonists and their effects on mental health conditions. [Explore Clinical Evidence](https://cedclinic.com/glucagon-like-peptide-1-receptor-agonists-mental-health-evidence/) [Cannabinoid Clinical Trials: GLP-1 Receptors and Mental Health](https://cedclinic.com/glp-1-receptor-agonists-mental-health-study/) Review of [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) assessing the impact of GLP-1 receptor agonists on [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/). [View Trials](https://cedclinic.com/glp-1-receptor-agonists-mental-health-study/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20%26%20GLP-1%20Receptor%20Mental%20Health%20Research&url=https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-research%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-research%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20%26%20GLP-1%20Receptor%20Mental%20Health%20Research%20https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-research%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).